Recor­dati ac­quires EU­SA Phar­ma and its 4 rare dis­ease drugs, but an­a­lysts ques­tion strat­e­gy be­hind the deal

An Ital­ian phar­ma com­pa­ny en­gi­neered a near­ly $850 mil­lion buy­out last week look­ing to ex­pand its rare dis­ease port­fo­lio and fur­ther soak up parts of the US mar­ket, but ques­tions re­main over the drugs in­volved and when they could see pa­tient up­take state­side.

Recor­dati shelled out the cash to ac­quire EU­SA Phar­ma and its port­fo­lio of four rare dis­ease drugs, the com­pa­nies an­nounced Fri­day, al­low­ing Recor­dati to po­si­tion it­self — by its own ac­count — for growth in the US. EU­SA’s top can­di­date for ex­pan­sion is os­ten­si­bly the neu­rob­las­toma drug Qarz­i­ba, ap­proved in the EU for high-risk, new­ly-di­ag­nosed in­di­vid­u­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER